MedTrace Logo

Metformin And Longevity

NCT02511665 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 185

Last updated 2015-07-30

No results posted yet for this study

Summary

This is a randomized, placebo-controlled, double-blind, window of opportunity study investigating the biological mechanism of metformin in prostate cancer.

Conditions

Interventions

DRUG

Metformin

Given metformin

RADIATION

PET-MRI Scan

Patients will under go 2 PET-MRI scans in the PET-MRI substudy arm one before treatment with metformin and one after

DRUG

Placebo

Given placebo

Sponsors & Collaborators

Principal Investigators

  • Sarah Rudman, MBBS BSc PhD · Guy's and St Thomas NHS Trust

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2017-07-31
Completion
2017-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02511665 on ClinicalTrials.gov